长春瑞滨联合顺铂对比多西他赛联合顺铂一线治疗晚期三阴性乳腺癌的临床研究  

Clinical Study on Vinorelbine Combined with Cisplatin vs. Docetaxel Combined with Cisplatin in the First-Line Treatment of Advanced Tri-Negative Breast Cancer

作　　者：何江涛[1] 王伟[1] 钟海鸣[1] 吴昱冶[1] 陈景胜[1] 莫淑芬 HE Jiangtao;WANG Wei;ZHONG Haiming;WU Yuye;CHEN flngsheng;MO Shufen(Guangdong Nongken Central Hospital,Zhanjiang 524002,China)

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《临床医学工程》2018年第12期1613-1614,共2页Clinical Medicine & Engineering

基　　金：2015年度湛江市第一批非资助科技攻关计划项目(项目编号:2015B01032)

摘　　要：目的研究晚期三阴性乳腺癌患者采取长春瑞滨+顺铂与多西他赛+顺铂治疗的临床价值。方法 40例晚期三阴性乳腺癌患者随机均分为两组,观察组给予长春瑞滨+顺铂,对照组给予多西他赛+顺铂,比较两组的治疗效果。结果观察组的客观缓解率、临床获益率均显著高于对照组(P <0.05)。两组的不良反应发生率、总生存时间、无进展生存时间无统计学差异(P>0.05)。结论长春瑞滨+顺铂与多西他赛+顺铂方案在晚期三阴性乳腺癌患者的治疗中均具有一定疗效,但前者的效果更好。Objective To study the clinical value of vinorelbine +cisplatin vs.docetaxel +cisplatin in the treatment of patients with advanced tri-negative breast cancer.Methods 40patients with advanced M-negative breast cancer were randomly divided into two groups equally.The observation group received vinorelbine +cisplatin,and the control group received docetaxel +cisplatin.The curative effects of two groups were compared.Results The objective remission rate and clinical benefit rate of observation group were significantly higher than those of control group (P<0.05).No statistical difference was found between the two groups in the incidence of adverse reactions,total survival time and progression-free survival time (P>0.05).Conclusions Both vinorelbine +cisplatin and docetaxel +cisplatin have certain curative effects in the treatment of patients with advanced tri-negative breast cancer,but the former has more significant effect.

关 键 词：长春瑞滨 顺铂 多西他赛 三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]